Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

752468

	registered interest
	date	17/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Parkinson's Disease: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government how much the NHS pays for a one year supply of Apomorphine for a patient with Parkinson's Disease; how much they estimate it costs to manufacture a year's supply of that drug; what assessment they have made of the difficulties of manufacturing Apomorphine to clinical standards; and whether they intend to take any steps to reduce the cost of that drug to the NHS.
	tabling member printed	Lord Lucas
	uin	HL914
	answer	answer is ministerial correction date of answer 19/07/2017 answer text <p>The drug cost to the National Health Service for a one year supply of Apomorphine for a patient with Parkinson's Disease is estimated to be in the region of £5,300 and £9,000, based on the usual daily dose of 3 – 30mg. However, the maximum daily is 100mg, so the annual cost for some patient’s treatment may be higher.</p><p>We have no estimate of the cost of manufacture. We are not aware of any particular issues relating to the manufacture of this drug. Pharmaceutical companies participate in either the voluntary pharmaceutical price regulation scheme (PPRS) or the statutory medicines price regulation scheme, both of which regulate the cost of medicines to the NHS. Products covered by the statutory scheme are subject to a 15% cut to their list price. Companies in the PPRS pay a percentage of sales to the Government when growth in NHS spending on medicines exceeds an agreed level. NHS purchasers may also negotiate discounts with pharmaceutical companies in addition to national price regulation.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 19/07/2017 15:12:09 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1879 label Biography information for Lord Lucas

752671

	registered interest
	date	17/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Eating Disorders
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the potential merits of introducing service standards for adults suffering from eating disorders for (a) access to services and (b) waiting times.
	tabling member constituency	Southampton, Itchen
	tabling member printed	Royston Smith
	uin	5142
	answer	answer is ministerial correction date of answer 19/07/2017 answer text <p>NHS England will develop evidence based treatment pathways across mental health services over the next five years in line with the recommendations of the Five Year Forward View for Mental Health. NHS England is working with the National Institute for Health and Care Excellence and the National Collaborating Centre for Mental Health to ensure that each pathway is fully informed by the available evidence and the views of experts by experience.</p><p> </p><p>The National Collaborating Centre for Mental Health is developing a pathway for adults with eating disorders, together with detailed implementation guidance for providers, over 2017/18.</p><p> </p><p>NHS England is also conducting a baseline audit to measure existing levels of investment, capacity and activity across inpatient and community services for adults with eating disorders.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 5008 question first answered 19/07/2017 13:23:22 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4478 label Biography information for Royston Smith

752673

	registered interest
	date	17/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Eating Disorders
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the average waiting time is for people with eating disorders to obtain medical treatment in (a) Southampton, (b) the South East and (c) England.
	tabling member constituency	Southampton, Itchen
	tabling member printed	Royston Smith
	uin	5140
	answer	answer is ministerial correction date of answer 19/07/2017 answer text <p>This information is not available in the format requested. NHS England publishes quarterly England only level data on waiting times for children and young people with an eating disorder. It can be accessed via the following link:</p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/cyped-waiting-times/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/cyped-waiting-times/</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 5007 question first answered 19/07/2017 13:25:01 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4478 label Biography information for Royston Smith